Business Leader, Investments

Paul Mampilly on Myriad Genetics and Precision Medicine

Paul Mampillly released a teaser pitch for its new Profits Unlimited newsletter. The newsletter will cover important news within the healthcare industry. For a yearly subscription fee of $97, readers will have the chance to get interesting and vital news on important and historical medical breakthroughs such as precision medicine. The pitch talks about precision medicine and what it can be able to do for humanity. Precision medicine involves studying of DNA and tailoring medicine to suit the patient’s needs. He talks of Myriad Genetics, a diagnostics and personalized medicine firm that specializes in cancer and non-cancer testing programs to help people who may be at risk of getting cancer.

Contribution

The company in question gets its revenue mainly through hereditary cancer screening, especially for colon and breast cancer. Through their tests, they identify the risk factors such as mutations that a person may have that may contribute to the risk of getting cancer. The company has performed well especially because more people are ordering for cancer tests, especially breast cancer tests, increasingly. Additionally, Myriad has a monopoly over other companies because they have been on the market for a few years. Hence they have a library of data on the mutations and variants of cancer.

Growth

The success of Myriad Genetics cannot be completely pegged on finances as their revenues have flattened out in the past four years and analysts expect the company’s earnings to drop. Their testing products are successful,and they are becoming foundational I the field over time. The company also has various growth prospects as they hope to diversify into new segments such as Vectra DA test and GeneSight test.

About Paul Mampillly

With up to 25 years of experience in investment Paul Mampilly is a trusted voice in his field. He has ventured into healthcare and biotechnology, which gives him an edge when it comes to issues such as precision medicine. He is also the founder of Capuchin Consulting. He got his MBA from Fordham University after which he got a job with Bankers Trust as an assistant portfolio manager.

Experience

Paul Mampilly later managed to work with ING and Deutsche Bank, adding on to his experience. He was further taken in by big corporations. Later, with Kinetics Asset Management, he managed to develop the hedge fund and grew the assets of Kinetics to $25 billion. He still graces the streets of the finance world but on a smaller scale as he helps common people make money and works as a research and investment analyst.

About Paul Mampillly: dailyreckoning.com/author/pmampilly/